BNTC - CIK 0001808898
The table below shows Benitec Biopharma Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 | Q3 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$3.35M | -$4.59M | -$4.58M | -$4.04M | -$4.28M | -$2.36M |
| Capital expenditure | - | - | - | - | $0.00 | $173.00K |
| Investing cash flow | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$173.00K |
| Dividends paid | - | - | - | - | - |
Benitec Biopharma Inc. reported operating cash flow of -$23.59M for fiscal year 2025. That is down 21.6% from -$19.40M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from $4.79M (FY 2019) to -$23.59M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $0.00 | $21.66M | $27.92M | $16.02M | - | - |